The Journey to Alzheimer’s Disease Diagnosis and Beyond Through Different Perspectives
DOI:
https://doi.org/10.58445/rars.2411Keywords:
Neuroscience, Alzheimers, Disease, Perspectives, Health Care, Patient, BiologyAbstract
Alzheimer’s disease (AD) is a prevalent neurodegenerative disease that affects at least 50 million people worldwide and is on the rise to affect about 152 million by 2050. This progressive disease burdens both the patients and their family/caregiver, bringing upon social, emotional, and financial challenges. The pathology of AD involves the build up of amyloid plaques and neurofibrillary tangles years before the onset and diagnosis of the disease. Signs of cognitive decline are often first reported to health care professionals before evaluation and eventual diagnosis and treatment. Initially, these signs are often diagnosed as mild cognitive impairment (MCI), but consistent further testing is required by health care professionals to monitor the progress of the disorder and its possible development into dementia and AD. Health care professionals utilize a combination of cognitive assessment, evidence of AD pathology, and other testing to diagnose the disease and rule out other potential causes of cognitive impairment. An earlier diagnosis of AD is beneficial in planning current and future care management for AD symptoms as well as navigating the limitations for the patient, their families/caregivers, and the health care professionals themselves. In this review article, the current etiology of AD will be discussed in addition to the methods of diagnosis and treatments for the disease. Additionally, the perspectives of health care providers, patients and their family, and society as a whole will be considered in the future of AD.
References
Adani, G., Filippini, T., Garuti, C., Malavolti, M., Vinceti, G., Zamboni, G., Tondelli, M., Galli, C., Costa, M., Vinceti, M., & Chiari, A. (2020). Environmental Risk Factors for Early-Onset Alzheimer’s Dementia and Frontotemporal Dementia: A Case-Control Study in Northern Italy. International Journal of Environmental Research and Public Health, 17(21), 7941. https://doi.org/10.3390/ijerph17217941
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 270–279. https://doi.org/10.1016/j.jalz.2011.03.008
Alzheimer's Association. (2024). Aducanumab Approved for Treatment of Alzheimer’s Disease. Alzheimer’s Disease and Dementia. https://www.alz.org/alzheimers-dementia/treatments/aducanumab
Alzheimer's Association. (2018). 2018 Alzheimer’s Disease Facts and Figures. Alzheimer’s Association. https://www.alz.org/media/HomeOffice/Facts%20and%20Figures/facts-and-figures.pdf
Alzheimer's Association. (2024). 2024 Alzheimer’s Disease Facts and Figures. Alzheimer’s Association. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
Alzheimer's Association. (2014). The most expensive disease: Alzheimer's disease. https://act.alz.org/site/DocServer/112114_Most_Expensive_Disease_Handout.pdf?docID=40161
Alzheimer's Impact Movement. (2024). Costs of Alzheimer’s to Medicare and Medicaid. Alzheimer's Impact. https://portal.alzimpact.org/media/serve/id/62509c7a54845
Alzheimer's Impact Movement. (2024). Dementia-Capable Workforce. Alzheimer's Impact. https://portal.alzimpact.org/media/serve/id/62509c7a54845
Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, Tammie. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., Goate, A. M., Morris, J. C., Karch, C. M., Xiong, C., Allegri, R., Mendez, P. C., Berman, S. B., Ikeuchi, T., Mori, H., Shimada, H., & Shoji, M. (2020). A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nature Medicine, 26(3), 398–407. https://doi.org/10.1038/s41591-020-0781-z
Bennett, T., Bray, D., & Neville, M. W. (2014). Suvorexant, a Dual Orexin Receptor Antagonist for the Management of Insomnia. Pharmacy and Therapeutics, 39(4), 264–266. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989084/
Brookmeyer, R., Gray, S., & Kawas, C. (1998). Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health, 88(9), 1337–1342. https://doi.org/10.2105/ajph.88.9.1337
Centers for Disease Control and Prevention. (2021). Demographic characteristics of people vaccinated against COVID-19: United States, December 2020–September 2021 (NCHS Data Brief No. 492). https://www.cdc.gov/nchs/data/databriefs/db492-tables.pdf#4
Centers for Disease Control and Prevention. (2023, October 24). Health Workers Face a Mental Health Crisis. Centers for Disease Control and Prevention. https://www.cdc.gov/vitalsigns/health-worker-mental-health/index.html
Chehrehnegar, N., Shati, M., Esmaeili, M., & Foroughan, M. (2021). Executive function deficits in mild cognitive impairment: evidence from saccade tasks. Aging & Mental Health, 1–9. https://doi.org/10.1080/13607863.2021.1913471
Commissioner, O. of the. (2023, May 11). FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s Disease. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease
CTG Labs - NCBI. (n.d.). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT03887455
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019). Alzheimer’s Disease Drug Development pipeline: 2019. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 5(1), 272–293. https://doi.org/10.1016/j.trci.2019.05.008
FDA. (2023, July 6). FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. FDA. https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
FDA-approved treatments for Alzheimer’s. (n.d.). https://www.alz.org/getmedia/4f4ca289-a2c6-4df9-8cdf-390365bd477e/alzheimers-dementia-fda-approved-treatments-for-alzheimers-ts.pdf
GBD 2019 Dementia Forecasting Collaborators. (2022). Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: an Analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, 7(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC8810394/
Grossberg, G., Lee, D., Slomkowski, M., Nanco Hefting, Chen, D., Hobart, M., & Cummings, J. (2024). Safety, Tolerability, and Efficacy of Brexpiprazole for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease: A 12-week Extension Trial (P11-9.011). Neurology, 102(17_supplement_1). https://doi.org/10.1212/wnl.0000000000204882
Havreng-Théry, C., Oquendo, B., Zolnowski-Kolp, V., Krolak-Salmon, P., François Bertin-Hugault, Lafuente-Lafuente, C., & Joël Belmin. (2024). Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study. Alzheimer's Research & Therapy, 16(1). https://doi.org/10.1186/s13195-024-01481-0
A Healthcare Provider’s Guide to Mild Cognitive Impairment (MCI): Diagnosis, pharmacologic management, non-pharmacologic management, and other considerations. n.d.). https://memory.ucsf.edu/sites/memory.ucsf.edu/files/wysiwyg/UCSF_MCI_Providers_7-13-17.pdf
Herring, W. J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., Stevens, J., Lines, C., & Michelson, D. (2020). Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial. Alzheimer’s & Dementia, 16(3), 541–551. https://doi.org/10.1002/alz.12035
HIGHLIGHTS OF PRESCRIBING INFORMATION. (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204569s006lbl.pdf
Homer, J., Alberts, M. J., Dawson, D. V., & Cook, G. M. (1994). Swallowing in Alzheimerʼs Disease. Alzheimer Disease & Associated Disorders, 8(3), 177–189. https://doi.org/10.1097/00002093-199408030-00004
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O’Brien, J., Passmore, P., Sheehan, B., & Juszczak, E. (2012). Donepezil and Memantine for Moderate-to-Severe Alzheimer’s Disease. New England Journal of Medicine, 366(10), 893–903. https://doi.org/10.1056/nejmoa1106668
Ivey-Stephenson, A. Z., Crosby, A. E., Hoenig, J. M., Gyawali, S., Park-Lee, E., & Hedden, S. L. (2022). Suicidal Thoughts and Behaviors Among Adults Aged ≥18 Years — United States, 2015–2019. MMWR. Surveillance Summaries, 71(1), 1–19. https://doi.org/10.15585/mmwr.ss7101a1
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., Alexander, M., Almdahl, I. S., Arnold, S. E., Baldeiras, I., Barthel, H., van Berckel, B. N. M., Bibeau, K., Blennow, K., Brooks, D. J., & van Buchem, M. A. (2015). Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA, 313(19), 1924. https://doi.org/10.1001/jama.2015.4668
Johns Hopkins Medicine. (2024). Swallowing disorders. Www.hopkinsmedicine.org. https://www.hopkinsmedicine.org/health/conditions-and-diseases/swallowing-disorders
Kalia, M. (2003). Dysphagia and aspiration pneumonia in patients with Alzheimer’s disease. Metabolism, 52, 36–38. https://doi.org/10.1016/s0026-0495(03)00300-7
Lee, D., Slomkowski, M., Hefting, N., Chen, D., Larsen, K. G., Kohegyi, E., Hobart, M., Cummings, J. L., & Grossberg, G. T. (2023). Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial. JAMA Neurology, 80(12). https://doi.org/10.1001/jamaneurol.2023.3810
“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China | News Release：2024. (n.d.). Eisai Co., Ltd. https://www.eisai.com/news/2024/news202403.html
McCullough, K. C., Bayles, K. A., & Bouldin, E. D. (2019). Language Performance of Individuals at Risk for Mild Cognitive Impairment. Journal of Speech, Language, and Hearing Research, 62(3), 706–722. https://doi.org/10.1044/2018_jslhr-l-18-0232
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 263–269. https://doi.org/10.1016/j.jalz.2011.03.005
Medicare.gov. (2019). Hospice Care Coverage. Medicare.gov. https://www.medicare.gov/coverage/hospice-care
Merck Receives Approval for BELSOMRA® (suvorexant) C-IV Label Update to Include Findings from Study of Insomnia in Patients with Mild-to-Moderate Alzheimer’s Disease. (n.d.). Merck.com. https://www.merck.com/news/merck-receives-approval-for-belsomra-suvorexant-c-iv-label-update-to-include-findings-from-study-of-insomnia-in-patients-with-mild-to-moderate-alzheimers-disease/
Monica Zigman Suchsland, Gaster, B., Raetz, J., Belza, B., McGuire, L. C., Olivari, B., Tracy, K., & Fitzpatrick, A. L. (2023). Developing a cognitive assessment toolkit for primary care: qualitative assessment of providers’ needs and perceptions of usability in clinical practice. BMC Health Services Research, 23(1). https://doi.org/10.1186/s12913-023-09991-7
National Institute on Aging. (2022, December 8). How is Alzheimer’s disease diagnosed? National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-symptoms-and-diagnosis/how-alzheimers-disease-diagnosed
National Library of Medicine. (2022, March 29). Non-drug interventions for Alzheimer’s disease. Nih.gov; Institute for Quality and Efficiency in Health Care (IQWiG). https://www.ncbi.nlm.nih.gov/books/NBK279355/
Prescription Drug Coverage. (2019). Medicare.gov. https://www.medicare.gov/coverage/prescription-drugs-outpatient
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004). The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months. Archives of Neurology, 61(2), 252. https://doi.org/10.1001/archneur.61.2.252
Research, C. for D. E. and. (2023). Drug Trials Snapshots: ADUHELM. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aduhelm
Research, C. for D. E. and. (2024). FDA approves treatment for adults with Alzheimer’s disease. FDA. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., & Engber, T. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 537(7618), 50–56. https://doi.org/10.1038/nature19323
Sideman, A. B., Ma, M., Hernandez de Jesus, A., Alagappan, C., Razon, N., Dohan, D., Chodos, A., Al-Rousan, T., Alving, L. I., Segal-Gidan, F., Rosen, H., Rankin, K. P., Possin, K. L., & Borson, S. (2023). Primary Care Practitioner Perspectives on the Role of Primary Care in Dementia Diagnosis and Care. JAMA Network Open, 6(9), e2336030. https://doi.org/10.1001/jamanetworkopen.2023.36030
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., Skovronsky, D. M., & TRAILBLAZER-ALZ 2 Investigators. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA, 330(6). https://doi.org/10.1001/jama.2023.13239
Solimando, L., Fasulo, M., Cavallero, S., Veronese, N., Smith, L., Vernuccio, L., Bolzetta, F., Dominguez, L. J., & Barbagallo, M. (2022). Suicide risk in caregivers of people with dementia: a systematic review and meta-analysis. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-022-02160-6
Sperling, R. A., Donohue, M. C., Raman, R., Sun, C.-K., Yaari, R., Holdridge, K., Siemers, E., Johnson, K. A., & Aisen, P. S. (2020). Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurology, 77(6), 735. https://doi.org/10.1001/jamaneurol.2020.0387
Stein Emil Vollset, Ababneh, H. S., Yohannes Habtegiorgis Abate, Cristiana Abbafati, Rouzbeh Abbasgholizadeh, Mohammadreza Abbasian, Hedayat Abbastabar, Magied, A., Samar Abd ElHafeez, Abdelkader, A., Abdelmasseh, M., Sherief Abd-Elsalam, Abdi, P., Abdollahi, M., Meriem Abdoun, Abdullahi, A., Abebe, M., Olumide Abiodun, Richard Gyan Aboagye, & Abolhassani, H. (2024). Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet, 403(10440), 2204–2256. https://doi.org/10.1016/s0140-6736(24)00685-8
United Nations. (2019). Global Issues: Ageing. United Nations. https://www.un.org/en/global-issues/ageing
U.S. Food and Drug Administration. (2021, June 7). FDA Grants Accelerated Approval for Alzheimer’s Drug. FDA. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
Van der Mussele, S., Le Bastard, N., Saerens, J., Somers, N., Mariën, P., Goeman, J., De Deyn, P. P., & Engelborghs, S. (2014). Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer’s dementia. Aging & Mental Health, 19(3), 247–257. https://doi.org/10.1080/13607863.2014.924900
Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2022). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/nejmoa2212948
Vermunt, L. (2019). Duration of preclinical, prodromal, and dementia stages of Alzheimer’s disease in relation to age, sex, and APOE genotype. Alzheimer’s & Dementia, 15(7), 888–898. https://doi.org/10.1016/j.jalz.2019.04.001
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013). Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. The Lancet Neurology, 12(10), 957–965. https://doi.org/10.1016/S1474-4422(13)70194-7
Wegmann, S., Biernat, J., & Mandelkow, E. (2021). A current view on Tau protein phosphorylation in Alzheimer’s disease. Current Opinion in Neurobiology, 69, 131–138. https://doi.org/10.1016/j.conb.2021.03.003
World Health Organization. (2023, March 15). Dementia. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dementia
World Health Organization. (2013). Definition and list of health professionals. Transforming and Scaling up Health Professionals’ Education and Training - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK298950
Downloads
Posted
Categories
License
Copyright (c) 2025 Deetya Potakamuri
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.